Propranolol Drug Market Report 2026

Propranolol Drug Market Overview

• Propranolol Drug market size has reached to $1.1 billion in 2025 • Expected to grow to $1.41 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Growing Prevalence of Cardiovascular Diseases Fuelling the Growth of the Propranolol Drug Market Due to Increasing Demand for Heart Rate and Blood Pressure Management • Market Trend: Improving Healthcare Access Through Advanced Medication Formulation Strategies • North America was the largest region in 2025.

What Is Covered Under Propranolol Drug Market?

Propranolol drug is a non-selective beta-blocker that lowers heart rate, blood pressure, cardiac workload, anxiety, and migraine prevention. It works by blocking the effects of adrenaline on the heart and blood vessels, reducing heart rate and blood pressure. Propranolol is also prescribed for managing symptoms of anxiety, particularly performance anxiety. The main types of propranolol drug dosage are tablets, injectable solutions, extended-release capsules, and oral solutions. Propranolol tablets are solid, oral medications containing propranolol hydrochloride, designed for quick absorption to treat conditions like high blood pressure, arrhythmias, and anxiety, with flexible dosing typically taken multiple times a day. It is applicable in various indications such as hypertension, angina pectoris, migraine prevention, post-traumatic stress disorder (PTSD), essential tremors, and therapeutic options in anxiety disorders, and is used by several end-users, including hospitals, clinics, home healthcare settings, nursing homes, and pharmaceutical companies.

What Is The Propranolol Drug Market Growth Forecast?

The propranolol drug market size is expected to see strong growth in the next few years. It will grow to $1.41 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, rising mental health disorders, demand for cost-effective therapies, expansion of generic drug markets, increased outpatient care. Major trends in the forecast period include sustained demand in cardiovascular disorders, increasing use in anxiety and migraine, expansion of generic propranolol, growth of extended-release formulations, inclusion in essential medicines programs.

Global Propranolol Drug Market Segmentation

1) By Dosage: Tablets, Injectable Solutions, Extended-Release Capsules, Oral Solution 2) By Indication-Based: Hypertension, Angina Pectoris, Migraine Prevention, Post-Traumatic Stress Disorder (PTSD), Essential Tremors, Therapeutic Options In Anxiety Disorders 3) By End-User: Hospitals, Clinics, Home Healthcare Settings, Nursing Homes Subsegments: 1) By Tablets: Standard Tablets, Chewable Tablets, Film-Coated Tablets 2) By Injectable Solutions: Intravenous Solutions, Intramuscular Solutions, Pre-Filled Syringes 3) By Extended-Release Capsules: 60 Milligrams (mg), 80 Milligrams (mg), 120 Milligrams (mg), 160 Milligrams (mg) 4) By Oral Solution: Liquid Suspension, Concentrated Oral Solution, Ready-To-Use Oral Solution

What Is The Driver Of The Propranolol Drug Market?

The growing prevalence of cardiovascular diseases is expected to propel the growth of the propranolol drug market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The rise in cardiovascular diseases can be attributed to unhealthy eating habits, where excessive consumption of processed foods and fats leads to higher cholesterol levels, increasing heart risks. Propranolol drug helps manage cardiovascular diseases by regulating heart rate and reducing blood pressure, making it ideal for patients with hypertension and arrhythmias. It enhances heart function and lowers the risk of heart attacks and strokes, improving cardiovascular health. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, 919,032 people in the US died from cardiovascular disease in 2023, representing approximately one in every three deaths nationwide. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the propranolol drug industry.

Key Players In The Global Propranolol Drug Market

Major companies operating in the propranolol drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Fresenius Kabi AG, Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Ipca Laboratories Limited, Mankind Pharma Ltd., Lannett Company Inc., Jubilant Pharma Holdings Inc., Actiza Pharmaceutical Private Limited, Mylan Laboratories Inc., Neurocon Inc., Neuracle Lifesciences Pvt. Ltd., Yabang Pharmaceutical Group Co. Ltd.

Global Propranolol Drug Market Trends and Insights

Major companies operating in the propranolol drug market are focusing on developing advanced products, such as extended-release formulation-based propranolol drugs, to enhance patient adherence and improve overall therapeutic outcomes. Extended-release formulations are designed to release the drug gradually over time, ensuring sustained therapeutic effects and reducing the need for frequent dosing, thereby improving patient adherence and treatment outcomes. For instance, in August 2023, Lupin Pharma Canada Ltd., a Canada-based pharmaceutical company, launched Propranolol long-acting capsules to address the Inderal long-acting (LA) discontinuation. The new extended-release formulation, available in 60 mg, 80 mg, 120 mg, and 160 mg, provides Canadian patients with consistent symptom relief and improves adherence, enhancing overall treatment outcomes and healthcare access.

What Are Latest Mergers And Acquisitions In The Propranolol Drug Market?

In December 2024, Exicure Inc., a US-based biotechnology company, partnered with GPCR Therapeutics Inc. With this partnership, Exicure Inc. aims to strengthen its position as a clinical-stage biotech company by acquiring key technical personnel and securing GPCR Therapeutics' proprietary CXCR4 inhibitor technology, enhancing its drug development in immuno-oncology, fibrosis, and obesity treatments. GPCR Therapeutics Inc. is a South Korea-based biopharmaceutical company that manufactures the propranolol drug.

Regional Insights

North America was the largest region in the propranolol drug market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Propranolol Drug Market?

The propranolol drug market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Propranolol Drug Market Report 2026?

The propranolol drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the propranolol drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.